

PROTOCOL

Validation of the Clinical Frailty Scale in vascular surgery: a protocol

Elks N,¹ Hitchman L,² Lathan R,^{1,2} Pathmanathan S,¹ Carradice D,^{1,2} Chetter J^{1,2}

1. Academic Vascular Surgical Unit, Hull University Teaching Hospitals National Health Service (NHS) Trust, Hull, UK

2. Hull York Medical School, University of Hull, Hull, UK

Corresponding author:

Dr Natasha Elks
Academic Vascular Surgical Unit,
Hull University Teaching Hospitals NHS Trust, Anlaby Road, Hull HU3 2JZ, UK
Email: natasha.elks2@nhs.net ; natasha_elks@yahoo.com

Received: 5th June 2025

Accepted: 21st July 2025

Online: 28th August 2025

Plain English Summary

Why we are undertaking this work: We have an ageing population in the UK. This means many people having surgery for vascular diseases are older, with a greater number of long-term health problems. This can affect their ability to care for themselves and others, to do things which are important to them, and to manage new or worsening health problems. This situation is called frailty. Having frailty may increase the risk of complications after surgical treatments, including a higher chance of death. If we can accurately assess frailty in patients having vascular surgery, this may lead to better understanding of their risks during and after an operation. This would help patients and doctors to make decisions about surgery and plan their care to reduce the chance of problems after surgery.

What we will do: The Rockwood Clinical Frailty Scale (CFS) is a tool which is used to screen people for frailty. However, we do not know if it can identify frailty in people with vascular diseases because this has not been specifically tested before. Some people with vascular disease are more likely to have problems with moving around and doing daily activities. We aim to find out if the CFS is good at detecting features of frailty in people undergoing vascular surgery. We also want to know how frailty affects the risk of complications after a vascular operation. We are planning to run a study looking at everyone who had a vascular operation between 3 August 2022 and 31 December 2023 at one hospital. This period has been carefully calculated to ensure we collect information on enough patients to answer the question. We will compare their CFS score against two other scores to assess frailty. The first is the electronic frailty index. This is currently used by all GPs in the UK. The second is the National Vascular Registry frailty level. By comparing the scores, we want to see which one is better at finding out who has frailty. We want to look at the association between these scoring systems and the presence of frailty on how well patients recover following treatment. This includes the complications they have and whether they survive their surgery. This will help us to support patients with frailty so that they have better results following their surgery.

What this means: This article outlines the steps we plan to follow to test whether the CFS is a good measure of frailty in patients having vascular surgery. When we have completed the research, the results will be shared with doctors and patients.

Abstract

Introduction: Frailty is a complex, dynamic and multifactorial syndrome. It is common in patients with vascular disease due to increased age and comorbidities. Identifying those with frailty preoperatively can help inform decisions about major interventional treatments and tailor postoperative care. This study aims to validate the Rockwood Clinical Frailty Scale (CFS) in patients undergoing major vascular surgery and determine whether the CFS can predict postoperative outcomes.

Methods: Validation study of the CFS as a measure of frailty in patients undergoing major vascular surgery in a single-centre retrospective cohort study. Consecutive patients undergoing major vascular surgery at one tertiary vascular centre between 3 August 2022 and 31 December 2023 will be included. The electronic Frailty Index will be used as the reference standard, against which the CFS will be assessed. Diagnostic accuracy will be compared in each of the following patient groups: major lower limb amputation, aortic aneurysm repair, lower limb revascularisation and carotid endarterectomy. Prognostication will explore the ability of CFS to predict mortality, complications, length of stay and discharge destination. A sample

size of 97 patients per subgroup will be required for an estimated sensitivity of 90% and specificity of 85%, based on local prevalence of documented frailty scores.

Conclusion: This study aims to validate the CFS in vascular patients and assess the ability of the CFS to predict postoperative outcomes. This will help to inform shared decision making and postoperative care.

Key words: vascular surgery, frailty, clinical frailty score, validation, protocol

Introduction

As life expectancy increases, so does the prevalence of older patients and age-related health conditions. Frailty is one such condition which has become increasingly recognised as a clinical syndrome, distinct from chronological age, disability and comorbidity.¹⁻³ A complex, dynamic and multifactorial syndrome, frailty may be theoretically defined as 'a state of increased vulnerability, resulting from age-associated declines in reserve and function across multiple physiological systems, such that the ability to cope with every day or acute stressors is compromised'.³⁻⁵ In the UK, increasing frailty in the community is associated with higher rates of adverse events such as falls, hospitalisation and institutionalisation, and death.⁶⁻⁹ Since frailty may be considered a measure of reduced physiological reserve,¹⁰ its severity has implications for patient response to medical and surgical therapy¹¹ and risk associated with therapeutic interventions.¹¹ Therefore, at the individual level, frailty can impact shared decision making and development of patient-centred care plans,^{7,8} while the effect of frailty on health economics and resource distribution^{8,12} may be felt by society.

Although the above definition is broadly accepted in theory, a single unified approach to assessing and quantifying frailty in a clinical setting remains elusive.^{13,14} The following operational models are some of the most commonly used and studied: frailty as an accumulation of deficits, such as the frailty index² (FI); frailty as a phenotype of low energetics, for example, Fried's frailty phenotype;³ frailty as derived from medical, nutritional, functional and psychological assessments, for example using Comprehensive Geriatric Assessment (CGA);¹⁵ frailty as a clinical judgement of function, such as using the Rockwood Clinical Frailty Scale (CFS).¹⁰

The plethora of available scales and scoring systems likely reflects uncertainty in the underlying components and pathophysiology that comprise frailty,¹⁰ leaving clinicians and policymakers alike without a clear directive of which assessment tool to use. Moreover, not all frailty measurements have been robustly validated, and many are used in a modified form rather than the original validated version,¹³ or used in populations other than those in which the tools were originally validated.¹⁶ For many specialties, the clinical value of frailty assessment depends on its validity in prognostication: is frailty an independent predictor of adverse outcomes?¹⁶⁻¹⁸ If frailty simply correlates with related factors such as chronological age¹⁹ or comorbidity burden,²⁰ then

time spent performing a designated frailty assessment could be better spent elsewhere.

Most patients who require major vascular surgery are chronologically and physiologically older: the majority are aged 65 or over²¹⁻²³ and have significant comorbidities such as diabetes, hypertension, cardiac disease, respiratory disease and a history of smoking.^{21,22} Moreover, frailty in these patients is becoming increasingly recognised as a preoperative risk factor which can impact postoperative recovery and is thus collected in the UK National Vascular Registry (NVR) quality improvement audit.²² There is potential for the use of frailty scores in prognostication for patients undergoing major vascular surgery,^{11,16} but the tools used need to be validated for use in a vascular cohort.²⁴

This study aims to explore whether the CFS, mapped onto the NVR four levels of frailty, is a valid method of quantifying frailty in patients who are undergoing major vascular surgery. The CFS is a rapid method of frailty assessment, making it ideal for use in acute and busy settings.¹¹ Clinicians consider comorbidity, cognitive impairment and disability to form a judgement of a patient's frailty status, based on pictures and descriptions of each level of frailty.¹⁰ This scoring system has been validated for identifying frailty in adults aged 65 or older in the UK,²⁵⁻²⁷ but has yet to be convincingly validated as a tool for identifying frailty itself within the cohort of inpatients with vascular disease. Previous studies have demonstrated that the CFS has a high specificity for identifying frailty in vascular outpatients and therefore could be useful in assessing frailty.^{28,29} These findings could be extrapolated to imply that the CFS is a valid measure of frailty in vascular inpatients; however, the studies done so far outside the clinic setting appear to consider the CFS as a prognostic factor only,³⁰⁻³² rather than seeking to evaluate the CFS against another measure of frailty. This study seeks to evaluate the evidence to determine whether the CFS measures and assesses frailty in the population of vascular inpatients.

Since 2019 the NVR has recommended that commonly used formal frailty assessments, including the CFS, may allow patients to be categorised as:

1. Not frail: well or managing well, routinely walking
2. Mild frailty: evident slowing such as difficulty walking outside
3. Moderate frailty: need help with some personal care or keeping house
4. Severe frailty: completely dependent for personal care.³³

The CFS allows clinicians to stratify patients by frailty level: if the CFS provides a consistently accurate estimate of the extent of frailty in patients with vascular disease, we aim to then explore whether frailty has an independent prognostic value for adverse outcomes in patients undergoing major vascular surgery.

Objectives

To validate the Clinical Frailty Scale (CFS) and NVR four levels of frailty in patients undergoing major vascular surgery and explore the prognostic value of CFS in predicting adverse events.

Outcomes

1. Sensitivity and specificity of CFS (and subsequently the NVR four levels of frailty) in diagnosing frailty in patients undergoing major vascular surgery. The electronic frailty index (eFI) will be the reference standard. This is a scoring system that uses the cumulative model of frailty: the patient's score is the fraction of deficits they are recorded as having from a list of 36 pre-specified diagnoses, deficits and disabilities. Conversely, the CFS is based on the phenotype model of frailty and describes differing degrees of physical performance^{10,34} based on standardised pictures and descriptions.
2. Risk associated with different CFS degrees of frailty in developing adverse events after major vascular surgery.
3. Assess the differences in frailty between groups of patients undergoing different vascular surgical procedures.

Methods

The study will be reported with reference to the Standards for Reporting Diagnostic accuracy studies (STARD) 2015 reporting guidance.³⁵

Study design

This is a single-centre validation study of the CFS frailty assessment tool in patients undergoing major vascular surgery.

Patient population

Consecutive patients admitted under the vascular services at a tertiary care centre from 3 August 2022 to 31 December 2023 will be included. This period has been calculated to ensure sufficient patients may be included for each subgroup, based on the volume of each type of surgery performed at the reference centre.

Only patients who undergo a major vascular surgery, as reportable to the NVR,²¹ will be included. This includes any patients undergoing major lower limb amputation (MLLA), for example, for chronic limb threatening ischaemia (CLTI) or diabetes-related foot complications; patients with abdominal aortic aneurysms (AAA) who undergo repair (open/endovascular); those presenting with CLTI or acute limb ischaemia (ALI) undergoing lower limb revascularisation (open/endovascular including angioplasty/hybrid); and patients with carotid disease undergoing revascularisation (open/endovascular).

Index test

We will compare the performance of a phenotype model of frailty assessment with the cumulative model of frailty assessment. The CFS will be validated in patients undergoing major vascular surgery. This is the preferred method of assessing frailty in the Centre for Perioperative Care guidelines,³⁶ and has previously been validated in hospital inpatients aged >65 years^{25,27,37} and in the outpatient setting for vascular patients;²⁸ however, there have been questions raised over the tool's applicability in those with lower limb ischaemia.³⁸

Reference standard

The eFI will be the reference standard. This tool is applied to all people over 65 years old to identify those at risk of being moderately or severely frail in the community setting.^{6,39} The eFI score is calculated as a fraction of 36 deficits determined from around 2000 GP read codes. This tool is used as a method of screening the community population, with the aim of identifying people who may benefit most from additional interventions^{6,40,41} to enable them to live well with frailty. As this tool is applied to everyone aged >65 years in England, all included patients aged >65 years should have an eFI in their records, and we will use this tool as the reference standard. For those patients aged <65 years, the eFI will be manually calculated from the GP read codes.

Data collection

Baseline data collection will include patient demographics, biochemical tests (haemoglobin, estimated glomerular filtration rate), comorbidities, American Society of Anaesthesiologists (ASA) grade and indication for the operation. The CFS is assigned prospectively, ahead of any surgical intervention, and all other data will be collected retrospectively.

Operative data will include the type of operation undertaken and the type of anaesthetic used.

Postoperative data will include admission to the intensive care unit (ICU), length of ICU stay, length of inpatient stay, input from dieticians and therapists (occupational, physical and speech and language); return to theatre, Clavien–Dindo classification of inpatient complications;^{42,43} discharge equipment and discharge destination.

Outcome data will be assessed at 30 days and 1 year, including re-admission, return to theatre, major adverse limb events (MALE, defined as amputation of the index limb, or major re-intervention such as new bypass graft; graft revision; angioplasty, thrombectomy)^{44–46} and major adverse cardiovascular events (MACE) defined as myocardial infarction, stroke and death (any cause).^{44–46}

Reference standard

The eFI score will be collected for all consecutive patients admitted under the vascular services and will be extracted from GP records or calculated using the eFI guidance note (Table 1) when the GP

Table 1 List of 36 electronic frailty index (eFI) deficit states⁶

Deficit: Disease state	Deficit: Abnormal laboratory value
1. Arthritis	21. Anaemia and haematinic deficiency
2. Atrial fibrillation	
3. Cerebrovascular disease	Deficit: Symptoms/signs
4. Chronic kidney disease	22. Dizziness
5. Diabetes	23. Dyspnoea
6. Foot problems	24. Falls
7. Fragility fracture	25. Memory and cognitive problems
8. Heart failure	26. Polypharmacy ⁹
9. Heart valve disease	27. Sleep disturbance
10. Hypertension	28. Urinary incontinence
11. Hypotension/syncope	29. Weight loss and anorexia
12. Ischaemic heart disease	
13. Osteoporosis	Deficit: Disability
14. Parkinsonism and tremor	30. Activity limitation
15. Peptic ulcer	31. Hearing impairment
16. Peripheral vascular disease	32. Housebound
17. Respiratory disease	33. Mobility and transfer problems
18. Skin ulcer	34. Requirement for care
19. Thyroid disease	35. Social vulnerability
20. Urinary system disease	36. Visual impairment

score is not available. This is calculated as follows: eFI = number of deficits/36 (total number of deficits).

Index test

The CFS will be extracted from the hospital medical records. The CFS is recorded contemporaneously on admission to the vascular ward by the clerking doctor: either a foundation trainee, vascular registrar, consultant vascular surgeon or vascular physician. Consistency is achieved by training all clerking doctors in how to calculate the CFS, highlighting that the score should reflect a patient’s pre-morbid state or baseline function.⁴⁷

It is recommended that a comprehensive history is taken about the patient’s usual function at least two weeks prior to acute illness onset, such that the CFS recorded reflects their baseline function and not their status whilst acutely unwell. Assessment of frailty should consider direct patient history, observation of the patient plus collateral history from the patient’s relatives. However, if the patient is dying, they will always be classified as CFS 9, and not by their baseline function.⁴⁸

Reliability

To examine inter-rater reliability, CFS scores assigned by resident doctors during initial assessment will be compared to a blinded assessment made by a consultant vascular physician (geriatrician). To examine intra-rater reliability, clinicians who assess the CFS will be asked to repeat the frailty assessment at least 24 hours after initial assessment. All reliability data will be collected as a separate prospective sub-study, with new patients.

Analysis

Data analysis

Descriptive statistics reporting the mean, median, standard

Table 2 Comparative cut-off levels for different levels of frailty (mild, moderate or severe) as measured by the NVR, CFS or eFI frailty assessment tools.

NVR category ³³	eFI ⁶	Rockwood CFS ¹⁰
1. Fit	0–0.12	1, 2
2. Mild frailty	0.13–0.24	3, 4, 5
3. Moderate frailty	0.25–0.36	6
4. Severe frailty	≥0.37	7, 8, 9

CFS, Clinical Frailty Scale; eFI, electronic frailty index; NVR, National

deviation and interquartile range will be reported for continuous data where appropriate. Categorical data will be reported as counts, frequencies and percentages. Data will be tested for normality. Data that are not normally distributed will be analysed using non-parametric tests. A p value of <0.05 will be interpreted as statistically significant.

Diagnostic accuracy

The frailty scores will be interpreted as in Table 2.

The following cut-off points will be explored:

- Not frail (NVR 1 and 2) versus Frail (NVR 3 and 4)
- Not frail (NVR 1) versus Frail (NVR 2, 3, 4)³³

Convergent validity will be used to assess validity of the CFS. For the CFS to be valid in patients undergoing major vascular surgery, it should agree with the eFI in more than 75% of cases and there should be a correlation of >0.5 between CFS and eFI. This will be tested using Spearman rank correlation. Analysis will be completed for all included patients and then explored across each of the four major patient cohorts – namely, those undergoing MLLA; repair of AAA; lower limb revascularisation; and carotid endarterectomy (CEA).

The diagnostic accuracy of CFS in identifying frailty compared with eFI will be explored by varying the test positivity cut-off point and constructing a receiver operator curve for each test positivity cut-off.

The sensitivity and specificity of CFS will be compared with eFI in a contingency table.

Reliability will be determined by test–retest correlation analysis from initial assessment score and second assessment score. This process will be repeated for inter-rater reliability with test–retest correlation analysis between blinded CFS scores allocated to the same patient.

Prognostication

If the CFS is shown to be an accurate way of diagnosing frailty in patients undergoing major vascular surgery, the role of CFS in predicting important patient outcomes will be explored. If CFS is not an accurate tool to diagnose frailty, eFI will be analysed for prognostication.

Table 3 Expected values used in sample size calculations and results of sample size calculations using these values^{52,53}

(a)		(b)	
Quantity	Value (%)	n values	Participants
Expected sensitivity	90	Sample size for sensitivity	87
Expected specificity	85	Sample size for specificity	82
Disease prevalence	40	Final sample size with 10% dropout	97
Precision (± expected)	10		
Confidence level	95		
Expected dropout rate	10		

A multivariate logistic regression model will be used to explore whether each of eFI, CFS and NVR categories are independently correlated with adverse outcomes. Patient outcomes will include mortality, ICU admission, MALE, MACE, length of stay and discharge destination.

Subgroup analysis

For AAA and lower limb revascularisation, a subgroup analysis will be performed to examine the validity and prognostication of CFS/eFI. In patients undergoing AAA repair, the subgroups will be rupture versus not rupture; infrarenal versus juxta-renal/suprarenal repair; and open versus endovascular repair. In patients undergoing lower limb revascularisation the subgroups will be indication for revascularisation (ischaemia, aneurysm, trauma, etc) and type of revascularisation. Ischaemia will be further subcategorised into acute limb ischaemia, intermittent claudication and CLTI.

Sample size

The local prevalence of frailty is taken to be 43%, based on a recent trust frailty audit.⁴⁹ An expected sensitivity of 90% and specificity of 85% have been estimated from other patient groups in the literature,^{50,51} since no studies have clearly established the sensitivity and specificity of CFS for identifying frailty in vascular patients. A 10% dropout rate (missing data) has been included in the sample size calculations as it is possible that not all patients will be assessed for frailty preoperatively. From the values shown in Table 3a,^{52,53} 97 patients will be required (Table 3b). For subgroup validity, this means 97 patients will be required per type of procedure (MLLA, AAA repair, lower limb revascularisation and CEA), giving a total sample size of 388 to determine the diagnostic validity of CFS compared with eFI across each vascular patient subgroup.

Ethics

The project was submitted as an audit to Hull University Teaching Hospital NHS Trust and has received local approval: 2022.111 Re-audit of the Prevalence of Frailty and the Impact on Surgical Management and Resource Use, for Vascular Inpatients Using the

National Vascular Registry (NVR) Frailty Classifications. Based on the UKRI decision tool, this study does not need independent NHS Research Ethics Committee (REC) approval. Data collected will be handled according to Good Clinical Practice guidelines, General Data Protection Regulation 2018 and information governance policies. Only study team members will have access to the data. All data will be anonymised. The study will not involve a change to routine patient care.

Dissemination of results

The results will be presented at local and national meetings and submitted to a peer review journal. A lay summary will be produced for patients and the public.

Discussion

Although there have been many studies of frailty in patients undergoing major vascular surgery,¹¹ there is no standardised approach to frailty assessment in these patients. The CFS is a rapid method of frailty screening which may have prognostication value but is yet to be convincingly validated in the population of vascular patients. This study will contribute to the growing field of frailty literature by validating the CFS and NVR four levels of frailty in vascular patients. It will also improve on existing data by validating these methods of frailty assessment in each subpopulation of the vascular cohort: patients undergoing MLLA, AAA repair, lower limb revascularisation and CEA. If the CFS is valid, this study may also offer insights into the prognostic value of frailty assessment, identifying whether baseline preoperative frailty is an independent risk factor for adverse outcomes in patients undergoing major vascular surgery.

The study is based in a large tertiary vascular centre in the North of England which has a catchment population of over 1.25 million people.⁵⁴ This will result in a diverse cohort of patients in terms of socioeconomic status, ethnic diversity and health status, so is likely to be generalisable to other settings in the UK. The method of validating frailty will consider different operations, indications and use an existing validating tool to assess frailty in the diverse vascular population. The study will also assess the reliability of CFS using a range of assessors with different experience of assessing frailty using CFS.

Potential caveats are: the results will only be applicable to patients who actually undergo surgery; external validity of the results may be limited as the data will be collected from a single centre; and potential biases from missing data due to the retrospective validation methods.

This protocol outlines a comprehensive validation study of CFS in patients undergoing vascular procedures reportable to the NVR. The results will provide key insights into the performance of some of the commonest frailty tools used in different populations of vascular patients. This information is vital when integrating frailty assessments into treatment decision making in future practice.

KEY MESSAGES

- Frailty is a complex, dynamic and multifactorial syndrome with implications for adverse health events.
- Frailty assessment in patients undergoing major vascular surgery needs to be validated for accuracy and prognostication.
- This protocol outlines the methods by which we aim to validate the Clinical Frailty Scale (CFS) for assessment of frailty in patients undergoing major vascular surgery, and any prognostication value the CFS may offer.

Conflict of Interest: None. We would like to declare that Professor Ian Chetter, who is a co-author of this protocol, also serves as Editor-in-Chief for *JVSGBI*.

Funding: Internally funded by the Academic Vascular Surgical Unit, Hull University Teaching Hospitals.

Reviewer acknowledgement: *JVSGBI* thanks Rob Sayers, Professor of Vascular Surgery, Glenfield Hospital, Leicester, and Eddie Caldwell, University of Salford, for their contribution to the peer review of this work.

References

- Howlett SE, Rutenburg AD, Rockwood K. The degree of frailty as a translational measure of health in aging. *Nat Aging* 2021;**1**(8):651–65. <https://doi.org/10.1038/s43587-021-00099-3>
- Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. *ScientificWorldJ* 2001;**1**:323–36. <https://doi.org/10.1100/tsw.2001.58>
- Fried LP, Tangen CM, Walston J, *et al.* Frailty in older adults: evidence for a phenotype. *J Gerontol* 2001;**56**(3):146–56. <https://doi.org/10.1093/gerona/56.3.M146>
- Xue QL. The frailty syndrome: definition and natural history. *Clin Geriatr Med* 2011;**27**(1):1–15. <https://doi.org/10.1016/j.cger.2010.08.009>
- Doody P, Lord JM, Greig CA, Whittaker AC. Frailty: pathophysiology, theoretical and operational definition(s), impact, prevalence, management and prevention, in an increasingly economically developed and ageing world. *Gerontology* 2023;**69**(8):927–45. <https://doi.org/10.1159/000528561>
- Clegg A, Bates C, Young J, *et al.* Development and validation of an electronic frailty index using routine primary care electronic health record data. *Age Ageing* 2016;**45**(3):353–60. <https://doi.org/10.1093/ageing/afw039>
- NHS England. Why is diagnosing frailty important? 2024. Available from: <https://www.england.nhs.uk/blog/martin-vernon-2/>
- Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. *The Lancet* 2019;**394**(10206):1365–75. [https://doi.org/10.1016/S0140-6736\(19\)31786-6](https://doi.org/10.1016/S0140-6736(19)31786-6)
- Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. *BMC Geriatr* 2017;**17**(1):230. <https://doi.org/10.1186/s12877-017-0621-2>
- Rockwood K, Song X, MacKnight C, *et al.* A global clinical measure of fitness and frailty in elderly people. *Can Med Assoc J* 2005;**173**(5):489–95. <https://doi.org/10.1503/cmaj.050051>
- Welsh SA, Pearson RC, Hussey K, Brittenden J, Orr DJ, Quinn T. A systematic review of frailty assessment tools used in vascular surgery research. *J Vasc Surg* 2023;**78**(6):1567–1579.e14. <https://doi.org/10.1016/j.jvs.2023.06.010>
- Brown P. Frailty. 2024. Available from: <https://bestpractice.bmj.com/topics/en-gb/3000323>
- Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: a review. *Eur J Intern Med* 2016;**31**:3–10. <https://doi.org/10.1016/j.ejim.2016.03.007>
- Buta BJ, Walston JD, Godino JG, *et al.* Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. *Ageing Res Rev* 2016;**26**:53–61. <https://doi.org/10.1016/j.arr.2015.12.003>
- Jones DM, Song X, Rockwood K. Operationalizing a frailty index from a standardized comprehensive geriatric assessment. *J Am Geriatr Soc* 2004;**52**(11):1929–33. <https://doi.org/10.1111/j.1532-5415.2004.52521.x>
- Houghton JSM, Nickinson ATO, Morton AJ, *et al.* Frailty factors and outcomes in vascular surgery patients: a systematic review and meta-analysis. *Ann Surg* 2020;**272**(2):266–76. <https://doi.org/10.1097/SLA.0000000000003642>
- Boreskie KF, Hay JL, Boreskie PE, Arora RC, Duhamel TA. Frailty-aware care: giving value to frailty assessment across different healthcare settings. *BMC Geriatr* 2022;**22**(1):13. <https://doi.org/10.1186/s12877-021-02722-9>
- Shamliyan T, Talley KMC, Ramakrishnan R, Kane RL. Association of frailty with survival: a systematic literature review. *Ageing Res Rev* 2013;**12**(2):719–36. <https://doi.org/10.1016/j.arr.2012.03.001>
- Mitnitski A, Howlett SE, Rockwood K. Heterogeneity of human aging and its assessment. *J Gerontol A Biol Sci Med Sci* 2017;**72**(7):877–84. <https://doi.org/10.1093/gerona/glw089>
- Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. *Lancet Public Health* 2018;**3**(7):e323–e332. [https://doi.org/10.1016/S2468-2667\(18\)30091-4](https://doi.org/10.1016/S2468-2667(18)30091-4)
- Watson S, Johal A, Li Q, *et al.* National Vascular Registry: 2023 State of the Nation Report. 2023. Available from: www.vsqip.org.uk
- Benson R, McGregor G, Shehata M, Imray C. Optimising fitness for major vascular surgery. *BMJ* 2019;**366**:l5002. <https://doi.org/10.1136/bmj.l5002>
- Amlani V, Ludwigs K, Rawshani A, *et al.* Major Adverse limb events in patients undergoing revascularisation for lower limb peripheral arterial disease: a nationwide observational study. *Eur J Vasc Endovasc Surg* 2024;**68**(6):737–45. <https://doi.org/10.1016/j.ejvs.2024.07.041>
- de Vet HCW, Terwee CB, Mokkink LB, Knol DL. *Measurement in Medicine*. Cambridge University Press, 2011. <https://doi.org/10.1017/CBO9780511996214>
- Broad A, Carter B, McKelvie S, Hewitt J. The convergent validity of the electronic Frailty Index (eFI) with the Clinical Frailty Scale (CFS). *Geriatrics* 2020;**5**(4):88. <https://doi.org/10.3390/geriatrics5040088>
- Carter B, Keevil VL, Anand A, *et al.* The prognostic and discriminatory utility of the Clinical Frailty Scale and Modified Frailty Index compared to age. *Geriatrics* 2022;**7**(5):87. <https://doi.org/10.3390/geriatrics7050087>
- Kay RS, Hughes M, Williamson TR, Hall AJ, Duckworth AD, Clement ND. The Clinical Frailty Scale can be used retrospectively to assess the frailty of patients with hip fracture: a validation study. *Eur Geriatr Med* 2022;**13**(5):1101–7. <https://doi.org/10.1007/s41999-022-00686-6>
- Mirabelli LG, Cosker RM, Kraiss LW, *et al.* Rapid methods for routine frailty assessment during vascular surgery clinic visits. *Ann Vasc Surg* 2018;**46**:134–41. <https://doi.org/10.1016/j.avsg.2017.08.010>
- Ayyash R, Knight J, Kothmann E, *et al.* Utility and reliability of the Clinical Frailty Scale in patients scheduled for major vascular surgery: a prospective, observational, multicentre observer-blinded study. *Perioper Med (Lond)* 2022;**11**(1):6. <https://doi.org/10.1186/s13741-022-00240-9>
- Otsuji H, Kanda D, Takumi T, *et al.* Association of wound, ischemia, and foot infection clinical stage with frailty and malnutrition in chronic limb-threatening ischemia patients undergoing endovascular intervention. *Vascular* 2022;**31**(3):504–12. <https://doi.org/10.1177/17085381221076943>
- Takeji Y, Yamaji K, Tomoi Y, *et al.* Impact of frailty on clinical outcomes in patients with critical limb ischemia. *Circ Cardiovasc Interv* 2018;**11**(7):e006778. <https://doi.org/10.1161/CIRCINTERVENTIONS.118.006778>
- Aitken SJ, Allard B, Altaf N, *et al.* Frail patients having vascular surgery during the early COVID-19 pandemic experienced high rates of adverse perioperative events and amputation. *ANZ J Surg* 2022;**92**(9):2305–11. <https://doi.org/10.1111/ans.17810>
- Vascular Services Quality Improvement Programme (VSQIP). Patient Frailty Score Guidance. 2024. Available from: <https://www.vsqip.org.uk/resource/patient-frailty-score-guidance/>
- Church S, Rogers E, Rockwood K, Theou O. A scoping review of the Clinical Frailty Scale. *BMC Geriatr* 2020;**20**(1):393. <https://doi.org/10.1186/s12877-020-01801-7>
- Cohen JF, Korevaar DA, Altman DG, *et al.* STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. *BMJ Open* 2016;**6**(11):e012799. <https://doi.org/10.1136/bmjopen-2016-e012799>
- Centre for Perioperative Care. Guideline for Perioperative Care for People

- Living with Frailty Undergoing Elective and Emergency Surgery. 2021. Available from: <https://www.cpoc.org.uk/sites/cpoc/files/documents/2021-09/CPOC-BGS-Frailty-Guideline-2021.pdf>
37. Ehlerl BA, Najafian A, Orion KC, Malas MB, Black JH, Abularrage CJ. Validation of a modified Frailty Index to predict mortality in vascular surgery patients. *J Vasc Surg* 2016;**63**(6):1595–1601.e2. <https://doi.org/10.1016/j.jvs.2015.12.023>
38. Hitchman L, Palmer J, Lathan R, *et al.* Frailty Assessment in UK Vascular Centres (FAVE): a survey to investigate data collection methods and impact on clinical practice. *J Vasc Soc GB Irel* 2023;**2**(2):69–75. <https://doi.org/10.54522/jvsgbi.2023.055>
39. Hollinghurst J, Fry R, Akbari A, *et al.* External validation of the electronic Frailty Index using the population of Wales within the Secure Anonymised Information Linkage Databank. *Age Ageing* 2019;**48**(6):922–6. <https://doi.org/10.1093/ageing/afz110>
40. NHS England. Identifying frailty. Available from: <https://www.england.nhs.uk/ourwork/clinical-policy/older-people/frailty/frailty-risk-identification/>
41. Abbasi M, Khera S, Dabravolskaj J, Garrison M, King S. Identification of frailty in primary care: feasibility and acceptability of recommended case finding tools within a primary care integrated seniors' program. *Gerontol Geriatr Med* 2019;**5**:233372141984815. <https://doi.org/10.1177/2333721419848153>
42. Dindo D, Demartines N, Clavien PA. Classification of surgical complications. *Ann Surg* 2004;**240**(2):205–13. <https://doi.org/10.1097/01.sla.0000133083.54934.ae>
43. Clavien PA, Barkun J, De Oliveira ML, *et al.* The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 2009;**250**(2):187–96. <https://doi.org/10.1097/SLA.0b013e3181b13ca2>
44. Conte MS, Geraghty PJ, Bradbury AW, *et al.* Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. *J Vasc Surg* 2009;**50**(6):1462–73.e1–3. <https://doi.org/10.1016/j.jvs.2009.09.044>
45. Fashandi AZ, Mehaffey JH, Hawkins RB, Kron IL, Upchurch GR, Robinson WP. Major adverse limb events and major adverse cardiac events after contemporary lower extremity bypass and infrainguinal endovascular intervention in patients with claudication. *J Vasc Surg* 2018;**68**(6):1817–23. <https://doi.org/10.1016/j.jvs.2018.06.193>
46. Saraidaridis JT, Patel VI, Lancaster RT, Cambria RP, Conrad MF. Applicability of the Society for Vascular Surgery's objective performance goals for critical limb ischemia to current practice of lower-extremity bypass. *Ann Vasc Surg* 2016;**30**:59–65. <https://doi.org/10.1016/j.avsg.2015.09.001>
47. Moorhouse P, Rockwood K. Frailty and its quantitative clinical evaluation. *J R Coll Physicians Edinb* 2012;**42**(4):333–40. <https://doi.org/10.4997/JRCPE.2012.412>
48. Mendiratta P, Schoo C, Latif R. Frailty. In: *Clinical Frailty Scale*. 2023;121–3. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559009/>
49. Hitchman L, Palmer J, Sethi S, Chetter I. Abstracts of the 2021 Association of Surgeons in Training International Surgical Conference vi47. *Br J Surg* 2021;**108**(6):znab259.117. <https://doi.org/10.1093/bjs/znab259.117>
50. Sze S, Pellicori P, Zhang J, Weston J, Clark AL. Identification of frailty in chronic heart failure. *JACC Heart Fail* 2019;**7**(4):291–302. <https://doi.org/10.1016/j.jchf.2018.11.017>
51. O'Caomh R, Costello M, Small C, *et al.* Comparison of frailty screening instruments in the emergency department. *Int J Environ Res Public Health* 2019;**16**(19):3626. <https://doi.org/10.3390/ijerph16193626>
52. Sample size calculator [cited 2024 Oct 17]. Available from: <https://wnarifin.github.io/ssc/ssnsp.html>
53. Buderer NM. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. *Acad Emerg Med* 1996;**3**(9):895–900. <https://doi.org/10.1111/j.1553-2712.1996.tb03538.x>
54. Dalton M. Remarkable people. Extraordinary place. 2021 [cited 2025 July 9]. Available from: <https://www.england.nhs.uk/wp-content/uploads/2022/09/hull-university-teaching-hospitals-nhs-trust-ara-20-21.pdf>